SHSE:688443'
s EV-to-Revenue Range Over the Past 10 Years
Min: 6691.91 Med: 14534.87 Max: 20616.63
Current: 8262.52
During the past 5 years, the highest EV-to-Revenue of Chongqing Genrix Biopharmaceutical Co was 20616.63. The lowest was 6691.91. And the median was 14534.87.
SHSE:688443's EV-to-Revenue is ranked worse than 99.03% of 1032
companies
in the Biotechnology industry
Industry Median: 7.65
vs SHSE:688443: 8262.52
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Chongqing Genrix Biopharmaceutical Co EV-to-Revenue Chart
Chongqing Genrix Biopharmaceutical Co Annual Data
Trend
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
-
-
-
-
10,206.28
Chongqing Genrix Biopharmaceutical Co Quarterly Data
Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's EV-to-Revenue
For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Genrix Biopharmaceutical Co's EV-to-Revenue Distribution in the Biotechnology Industry
Chongqing Genrix Biopharmaceutical Co's current Enterprise Value is ¥9,229.24 Mil.
Chongqing Genrix Biopharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) EV-to-Revenue Explanation
Chongqing Genrix Biopharmaceutical Co's share price for today is ¥30.36.
Chongqing Genrix Biopharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Genrix Biopharmaceutical Co EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Business Description
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:688443 has been successfully added to your 